Table 3.

Patient characteristics and pMMA and uMMA values of a subset of individuals from the MARLINA trial. Arithmetic means and standard deviations of MMA values in plasma and urine per point in time and group.

MMA Levels point in time	Plasma [nmol/L]		Urine [µmol/mmol Creatinine]
	V3	V7	V3	V7
All	222 ± 131	248 ± 149	2.05 ± 2.78	2.14 ± 3.17
White	152 ± 92	154 ± 102	1.4 ± 2.3	1.34 ± 2.59
Asian*	248 ± 139	278 ± 150	2.3 ± 2.9	2.42 ± 3.31
Linagliptin	225 ± 145	246 ± 158	1.77 ± 2.23	1.99 ± 3.02
Placebo	220 ± 117	250 ± 140	2.34 ± 3.2	2.29 ± 3.31

MMA methylmalonic acid; V3 baseline; V7 end of study.

*Significantly higher plasma and urine MMA levels in Asian patients compared with White patients (Welch -test).